Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 31, Issue 39
  5. Article
Volume 31, Issue 39
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Alcohol use disorder (AUD) affects millions of people worldwide. It is characterized by a strong physiological and psychological craving to consume large amounts of alcohol despite adverse consequences. Alcohol use disorder carries a large health and economic burden on society. Despite its prevalence, AUD is still severely undertreated. The precise molecular mechanisms of how alcohol addiction forms are yet unknown. However, previous studies on animal models show that along with the μ-opioid receptors, the D2R dopamine receptors may also be involved in alcohol craving and reward pathways. Currently, there is a limited number of treatment strategies for alcohol use disorder, which include several medications and therapy. By understanding the limitations of current treatment options and exploring new potential targets, it could be possible to find more effective ways of treating AUD in the future.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673248999231013043249
2023-10-26
2025-01-14

  • From This Site

    /content/journals/cmc/10.2174/0109298673248999231013043249
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SudhinarasetM. WigglesworthC. TakeuchiD.T. Social and cultural contexts of alcohol use: Influences in a social-ecological framework.Alcohol Res.2016381354527159810
     [Google Scholar]
  2. MorrisH. LarsenJ. CatterallE. MossA.C. DombrowskiS.U. Peer pressure and alcohol consumption in adults living in the UK: A systematic qualitative review.BMC Public Health2020201101410.1186/s12889‑020‑09060‑232631278
     [Google Scholar]
  3. MorenoM.A. WhitehillJ.M. Influence of social media on alcohol use in adolescents and young adults.Alcohol Res.20143619110026259003
     [Google Scholar]
  4. TuckerJ.S. RodriguezA. GreenH.D.Jr PollardM.S. Trajectories of alcohol use and problems during the COVID-19 pandemic: The role of social stressors and drinking motives for men and women.Drug Alcohol Depend.202223210928510.1016/j.drugalcdep.2022.10928535033955
     [Google Scholar]
  5. RehmJ. The risks associated with alcohol use and alcoholism.Alcohol Res. Health201134213514322330211
     [Google Scholar]
  6. SinghS.K. RamananV.V. A study on alcohol use and its related health and social problems in rural Puducherry, India.J. Family Med. Prim. Care20165480480810.4103/2249‑4863.20117528348995
     [Google Scholar]
  7. KassymL. KussainovaA. SemenovaY. KussainovA. MarapovD. ZhanaspayevM. UrazalinaZ. AkhmetovaA. TokanovM. SmailY. BjørklundG. Worldwide prevalence of alcohol use in non-fatally injured motor vehicle drivers: A systematic review and meta-analysis.Healthcare202311575810.3390/healthcare1105075836900763
     [Google Scholar]
  8. RumgayH. MurphyN. FerrariP. SoerjomataramI. Alcohol and cancer: Epidemiology and biological mechanisms.Nutrients2021139317310.3390/nu1309317334579050
     [Google Scholar]
  9. XieX. FengK. WangJ. ZhangM. HongJ. ZhangH. Comprehensive visual electrophysiological measurements discover crucial changes caused by alcohol addiction in humans: Clinical values in early prevention of alcoholic vision decline.Front. Neural Circuits20221691288310.3389/fncir.2022.91288336034334
     [Google Scholar]
  10. SutherlandG.T. SheedyD. KrilJ.J. Neuropathology of alcoholism.Handb. Clin. Neurol.201412560361510.1016/B978‑0‑444‑62619‑6.00035‑525307599
     [Google Scholar]
  11. BanerjeeN. Neurotransmitters in alcoholism: A review of neurobiological and genetic studies.Indian J. Hum. Genet.2014201203110.4103/0971‑6866.13275024959010
     [Google Scholar]
  12. WackernahR.C. MinnickM.J. ClappP. Alcohol use disorder: Pathophysiology, effects, and pharmacologic options for treatment.Subst. Abuse Rehabil.2014511224648792
     [Google Scholar]
  13. HussainR. ZubairH. PursellS. ShahabM. Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches.Brain Sci.20188917710.3390/brainsci809017730223579
     [Google Scholar]
  14. MartinezJ.A. SteinleyD. SherK.J. Deliberate induction of alcohol tolerance: Empirical introduction to a novel health risk.Addiction2010105101767177010.1111/j.1360‑0443.2010.03042.x20840199
     [Google Scholar]
  15. Haass-KofflerC.L. PerciballiR. Alcohol tolerance in human laboratory studies for development of medications to treat alcohol use disorder.Alcohol Alcohol.202055212913510.1093/alcalc/agz10331950152
     [Google Scholar]
  16. CederbaumA.I. Alcohol metabolism.Clin. Liver Dis.201216466768510.1016/j.cld.2012.08.00223101976
     [Google Scholar]
  17. YangW. SinglaR. MaheshwariO. FontaineC.J. Gil-MohapelJ. Alcohol use disorder: Neurobiology and therapeutics.Biomedicines2022105119210.3390/biomedicines1005119235625928
     [Google Scholar]
  18. Diagnostic and statistical manual of mental disordersAmerican Psychiatric Association2013
     [Google Scholar]
  19. RitchieH. RoserM. Alcohol ConsumptionAvailable from: https://ourworldindata.org/alcohol-consumption 2018
  20. McCradyB.S. FlanaganJ.C. The role of the family in alcohol use disorder recovery for adults.Alcohol Res202141106
     [Google Scholar]
  21. HuebnerR.B. KantorL.W. Advances in alcoholism treatment.Alcohol Res. Health201133429529923580014
     [Google Scholar]
  22. CarrollK.M. KilukB.D. Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again.Psychol. Addict. Behav.201731884786110.1037/adb000031128857574
     [Google Scholar]
  23. FlanaganJ.C. JonesJ.L. JarneckeA.M. BackS.E. Behavioral treatments for alcohol use disorder and post-traumatic stress disorder.Alcohol Res.201839218119231198657
     [Google Scholar]
  24. WinslowB.T. OnyskoM. HebertM. Medications for alcohol use disorder.Am. Fam. Physician201693645746526977830
     [Google Scholar]
  25. MasonB.J. HeyserC.J. Alcohol use disorder: The role of medication in recovery.Alcohol Res202141107
     [Google Scholar]
  26. AntonR.F. O’MalleyS.S. CirauloD.A. CislerR.A. CouperD. DonovanD.M. GastfriendD.R. HoskingJ.D. JohnsonB.A. LoCastroJ.S. LongabaughR. MasonB.J. MattsonM.E. MillerW.R. PettinatiH.M. RandallC.L. SwiftR. WeissR.D. WilliamsL.D. ZwebenA. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial.JAMA2006295172003201710.1001/jama.295.17.200316670409
     [Google Scholar]
  27. WangS. Historical review: Opiate addiction and opioid receptors.Cell Transplant.201928323323810.1177/096368971881106030419763
     [Google Scholar]
  28. PathanH. WilliamsJ. Basic opioid pharmacology: An update.Br. J. Pain201261111610.1177/204946371243849326516461
     [Google Scholar]
  29. Le MerrerJ. BeckerJ.A.J. BefortK. KiefferB.L. Reward processing by the opioid system in the brain.Physiol. Rev.20098941379141210.1152/physrev.00005.200919789384
     [Google Scholar]
  30. DhaliwalA. GuptaM. In StatPearls; StatPearls Publishing Copyright © 2022.Treasure Island, FLStatPearls Publishing LLC2022
     [Google Scholar]
  31. KoehlA. HuH. MaedaS. ZhangY. QuQ. PaggiJ.M. LatorracaN.R. HilgerD. DawsonR. MatileH. SchertlerG.F.X. GranierS. WeisW.I. DrorR.O. ManglikA. SkiniotisG. KobilkaB.K. Structure of the µ-opioid receptor–Gi protein complex.Nature2018558771154755210.1038/s41586‑018‑0219‑729899455
     [Google Scholar]
  32. PasternakG.W. Opioids and their receptors: Are we there yet?Neuropharmacology201476Pt B198203
     [Google Scholar]
  33. CristR.C. BerrettiniW.H. Pharmacogenetics of OPRM1.Pharmacol. Biochem. Behav.2014123253310.1016/j.pbb.2013.10.01824201053
     [Google Scholar]
  34. FengY. HeX. YangY. ChaoD. LazarusL.H. XiaY. Current research on opioid receptor function.Curr. Drug Targets201213223024610.2174/13894501279920161222204322
     [Google Scholar]
  35. BelloM. Molecular basis of inhibitory mechanism of naltrexone and its metabolites through structural and energetic analyses.Molecules20222715491910.3390/molecules2715491935956868
     [Google Scholar]
  36. SiudaE.R. CopitsB.A. SchmidtM.J. BairdM.A. Al-HasaniR. PlanerW.J. FunderburkS.C. McCallJ.G. GereauR.W.IV BruchasM.R. Spatiotemporal control of opioid signaling and behavior.Neuron201586492393510.1016/j.neuron.2015.03.06625937173
     [Google Scholar]
  37. BeraI. LaskarA. GhoshalN. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: A comparative study.J. Mol. Model.20111751207122110.1007/s00894‑010‑0803‑820661609
     [Google Scholar]
  38. ManglikA. KruseA.C. KobilkaT.S. ThianF.S. MathiesenJ.M. SunaharaR.K. PardoL. WeisW.I. KobilkaB.K. GranierS. Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.Nature2012485739832132610.1038/nature1095422437502
     [Google Scholar]
  39. ArimontM. HoffmannC. de GraafC. LeursR. Chemokine receptor crystal structures: What Can be learned from them?Mol. Pharmacol.201996676577710.1124/mol.119.11716831266800
     [Google Scholar]
  40. Ben HamidaS. BoulosL.J. McNicholasM. CharbogneP. KiefferB.L. Mu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking.Addict. Biol.2019241283910.1111/adb.1257629094432
     [Google Scholar]
  41. HermannD. HirthN. ReimoldM. BatraA. SmolkaM.N. HoffmannS. KieferF. NooriH.R. SommerW.H. ReischlG. la FougèreC. MannK. SpanagelR. HanssonA.C. Low μ-opioid receptor status in alcohol dependence identified by combined positron emission tomography and post-mortem brain analysis.Neuropsychopharmacology201742360661410.1038/npp.2016.14527510425
     [Google Scholar]
  42. LiL ChenJ LiYQ The downregulation of opioid receptors and neuropathic pain.Int J Mol Sci.2023246598110.3390/ijms24065981
     [Google Scholar]
  43. OhgiY. Alcohol dependence and opioid receptor —Pharmacological profile of nalmefene—.Nippon Yakurigaku Zasshi2020155314514810.1254/fpj.1913932378631
     [Google Scholar]
  44. MitchellJ.M. O’NeilJ.P. JanabiM. MarksS.M. JagustW.J. FieldsH.L. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens.Sci. Transl. Med.20124116116ra610.1126/scitranslmed.300290222238334
     [Google Scholar]
  45. SinghD. SaadabadiA. In StatPearls; StatPearls Publishing Copyright © 2022.Treasure Island, FLStatPearls Publishing LLC2022
     [Google Scholar]
  46. SrivastavaA.B. GoldM.S. Naltrexone: A history and future directions.Cerebrum20182018
     [Google Scholar]
  47. MaloneM. McDonaldR. VittitowA. ChenJ. ObiR. SchatzD. TofighiB. GarmentA. KermackA. GoldfeldK. GoldH. LaskaE. RotrosenJ. LeeJ.D. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).Contemp. Clin. Trials20198110210910.1016/j.cct.2019.04.00630986535
     [Google Scholar]
  48. HeiligM. GoldmanD. BerrettiniW. O’BrienC.P. Pharmacogenetic approaches to the treatment of alcohol addiction.Nat. Rev. Neurosci.2011121167068410.1038/nrn311022011682
     [Google Scholar]
  49. MikusN. KorbS. MassaccesiC. GaustererC. GrafI. WilleitM. EiseneggerC. LammC. SilaniG. MathysC. Effects of dopamine D2/3 and opioid receptor antagonism on the trade-off between model-based and model-free behaviour in healthy volunteers.eLife202211e7966110.7554/eLife.7966136468832
     [Google Scholar]
  50. DolanR.J. DayanP. Goals and habits in the brain.Neuron201380231232510.1016/j.neuron.2013.09.00724139036
     [Google Scholar]
  51. Juárez OlguínH. Calderón GuzmánD. Hernández GarcíaE. Barragán MejíaG. The role of dopamine and its dysfunction as a consequence of oxidative stress.Oxid. Med. Cell. Longev.2016201611310.1155/2016/973046726770661
     [Google Scholar]
  52. FrancoR. Reyes-ResinaI. NavarroG. Dopamine in health and disease: Much more than a neurotransmitter.Biomedicines20219210910.3390/biomedicines902010933499192
     [Google Scholar]
  53. BaikJ.H. Dopamine signaling in reward-related behaviors.Front. Neural Circuits2013715210.3389/fncir.2013.0015224130517
     [Google Scholar]
  54. YangS. Boudier-RevéretM. ChooY.J. ChangM.C. Association between chronic pain and alterations in the mesolimbic dopaminergic system.Brain Sci.2020101070110.3390/brainsci1010070133023226
     [Google Scholar]
  55. TaylorA.M.W. BeckerS. SchweinhardtP. CahillC. Mesolimbic dopamine signaling in acute and chronic pain.Pain201615761194119810.1097/j.pain.000000000000049426797678
     [Google Scholar]
  56. MishraA. SinghS. ShuklaS. Physiological and functional basis of dopamine receptors and their role in neurogenesis: Possible implication for Parkinson’s disease.J. Exp. Neurosci.20181210.1177/117906951877982929899667
     [Google Scholar]
  57. PrasadP. AmbekarA. VaswaniM. Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: A preliminary study.BMC Med. Genet.20101112410.1186/1471‑2350‑11‑2420146828
     [Google Scholar]
  58. MaH. ZhuG. The dopamine system and alcohol dependence.Shanghai Jingshen Yixue2014262616825092951
     [Google Scholar]
  59. FeltmannK. Borroto-EscuelaD.O. RüeggJ. PintonL. de Oliveira SergioT. NarváezM. Jimenez-BeristainA. EkströmT.J. FuxeK. SteenslandP. Effects of long-term alcohol drinking on the dopamine d2 receptor: Gene expression and heteroreceptor complexes in the striatum in rats.Alcohol. Clin. Exp. Res.201842233835110.1111/acer.1356829205397
     [Google Scholar]
  60. BocarslyM.E. da Silva e SilvaD. KolbV. LudermanK.D. ShashikiranS. RubinsteinM. SibleyD.R. DobbsL.K. AlvarezV.A. A mechanism linking two known vulnerability factors for alcohol abuse: Heightened alcohol stimulation and low striatal dopamine D2 receptors.Cell Rep.201929511471163.e510.1016/j.celrep.2019.09.05931665630
     [Google Scholar]
  61. KampF. ProebstlL. PenzelN. AdorjanK. IlankovicA. PogarellO. KollerG. SoykaM. FalkaiP. KoutsoulerisN. KambeitzJ. Effects of sedative drug use on the dopamine system: A systematic review and meta-analysis of in vivo neuroimaging studies.Neuropsychopharmacology201944466066710.1038/s41386‑018‑0191‑930188512
     [Google Scholar]
  62. GleichT. SpittaG. ButlerO. ZachariasK. AydinS. SeboldM. GarbusowM. RappM. SchubertF. BuchertR. HeinzA. GallinatJ. Dopamine D2/3 receptor availability in alcohol use disorder and individuals at high risk: Towards a dimensional approach.Addict. Biol.2021262e1291510.1111/adb.1291532500613
     [Google Scholar]
  63. MissaleC. Nerve growth factor, D2 receptor isoforms, and pituitary tumors.Endocrine201242346646710.1007/s12020‑012‑9756‑222833430
     [Google Scholar]
  64. SalinasA.G. MateoY. CarlsonV.C.C. StinnettG.S. LuoG. SeasholtzA.F. GrantK.A. LovingerD.M. Long-term alcohol consumption alters dorsal striatal dopamine release and regulation by D2 dopamine receptors in rhesus macaques.Neuropsychopharmacology20214681432144110.1038/s41386‑020‑00938‑833452430
     [Google Scholar]
  65. TiceA.L. LaudatoJ.A. RossettiM.L. WolffC.A. EsserK.A. LeeC. LangC.H. ViedC. GordonB.S. SteinerJ.L. Binge alcohol disrupts skeletal muscle core molecular clock independent of glucocorticoids.Am. J. Physiol. Endocrinol. Metab.20213215E606E62010.1152/ajpendo.00187.202134541876
     [Google Scholar]
  66. SharmaR. ParikhM. MishraV. SahotaP. ThakkarM. Activation of dopamine D2 receptors in the medial shell region of the nucleus accumbens increases Per1 expression to enhance alcohol consumption.Addict. Biol.2022272e1313310.1111/adb.1313335032086
     [Google Scholar]
  67. RamchandaniV.A. UmhauJ. PavonF.J. Ruiz-VelascoV. MargasW. SunH. DamadzicR. EskayR. SchoorM. ThorsellA. SchwandtM.L. SommerW.H. GeorgeD.T. ParsonsL.H. HerscovitchP. HommerD. HeiligM. A genetic determinant of the striatal dopamine response to alcohol in men.Mol. Psychiatry201116880981710.1038/mp.2010.5620479755
     [Google Scholar]
  68. HillemacherT. RheinM. BurkertA. HeberleinA. WilhelmJ. GlahnA. MuschlerM.A.N. KahlK.G. KornhuberJ. BleichS. FrielingH. DNA-methylation of the dopamin receptor 2 gene is altered during alcohol withdrawal.Eur. Neuropsychopharmacol.201929111250125710.1016/j.euroneuro.2019.09.00231530416
     [Google Scholar]
  69. SwiftR.M. AstonE.R. Pharmacotherapy for alcohol use disorder: Current and emerging therapies.Harv. Rev. Psychiatry201523212213310.1097/HRP.000000000000007925747925
     [Google Scholar]
  70. KellyJ.F. HumphreysK. FerriM. Alcoholics Anonymous and other 12-step programs for alcohol use disorder.Cochrane Database Syst. Rev.202033CD01288032159228
     [Google Scholar]
  71. WnukM. The beneficial role of involvement in alcoholics anonymous for existential and subjective well-being of alcohol-dependent individuals? the model verification.Int. J. Environ. Res. Public Health2022199517310.3390/ijerph1909517335564567
     [Google Scholar]
  72. SrivastavaA.B. Sanchez-PeñaJ. LevinF.R. MarianiJ.J. PatelG.H. NaqviN.H. Drinking reduction during cognitive behavioral therapy for alcohol use disorder is associated with a reduction in anterior insula-bed nucleus of the stria terminalis resting-state functional connectivity.Alcohol. Clin. Exp. Res.20214581596160610.1111/acer.1466134342012
     [Google Scholar]
  73. CorneliusJ.R. DouaihyA.B. KirisciL. DaleyD.C. Longer-term effectiveness of cbt in treatment of comorbid aud/mdd adolescents.Int. J. Med. Biol. Front.201319225339844
     [Google Scholar]
  74. WitkiewitzK. LittenR.Z. LeggioL. Advances in the science and treatment of alcohol use disorder.Sci. Adv.201959eaax404310.1126/sciadv.aax404331579824
     [Google Scholar]
  75. WilsonA.D. RoosC.R. RobinsonC.S. SteinE.R. ManuelJ.A. EnkemaM.C. BowenS. WitkiewitzK. Mindfulness-based interventions for addictive behaviors: Implementation issues on the road ahead.Psychol. Addict. Behav.201731888889610.1037/adb000031929072477
     [Google Scholar]
  76. KoreckiJ.R. SchwebelF.J. VotawV.R. WitkiewitzK. Mindfulness-based programs for substance use disorders: A systematic review of manualized treatments.Subst. Abuse Treat. Prev. Policy20201515110.1186/s13011‑020‑00293‑332727559
     [Google Scholar]
  77. KranzlerH.R. SoykaM. Diagnosis and pharmacotherapy of alcohol use disorder.JAMA2018320881582410.1001/jama.2018.1140630167705
     [Google Scholar]
  78. BrünenS. BekierN.K. HiemkeC. KorfF. WiedemannK. JahnH. KieferF. Therapeutic drug monitoring of naltrexone and 6β-naltrexol during anti-craving treatment in alcohol dependence: Reference ranges.Alcohol Alcohol.2019541515510.1093/alcalc/agy06730260366
     [Google Scholar]
  79. RösnerS. Hackl-HerrwerthA. LeuchtS. LehertP. VecchiS. SoykaM. Acamprosate for alcohol dependence.Cochrane Database Syst. Rev.20109CD00433220824837
     [Google Scholar]
  80. KalkN.J. Lingford-HughesA.R. The clinical pharmacology of acamprosate.Br. J. Clin. Pharmacol.201477231532310.1111/bcp.1207023278595
     [Google Scholar]
  81. CarpenterJ.E. LaPradD. DayoY. DeGroteS. WilliamsonK. An overview of pharmacotherapy options for alcohol use disorder.Fed. Pract.20183510485830766325
     [Google Scholar]
  82. PedersenB. AskgaardG. JørgensenC. OppedalK. TønnesenH. In Cochrane Database Syst Rev; Copyright © 2018 The Cochrane Collaboration.John Wiley & Sons, Ltd.2018Vol. 2018
     [Google Scholar]
  83. HeikkinenM. TaipaleH. TanskanenA. Mittendorfer-RutzE. LähteenvuoM. TiihonenJ. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.Addiction202111681990199810.1111/add.1538433394527
     [Google Scholar]
  84. EdelmanE.J. MooreB.A. HoltS.R. HansenN. KyriakidesT.C. VirataM. BrownS.T. JusticeA.C. BryantK.J. FiellinD.A. FiellinL.E. Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: A randomized-controlled trial.AIDS Behav.201923121122110.1007/s10461‑018‑2241‑z30073637
     [Google Scholar]
  85. SantosG.M. IkedaJ. CoffinP. WalkerJ. MathesonT. AliA. McLaughlinM. JainJ. ArenanderJ. VittinghoffE. BatkiS. Targeted oral naltrexone for mild to moderate alcohol use disorder among sexual and gender minority men: A randomized trial.Am. J. Psychiatry20221791291592610.1176/appi.ajp.2022033536285404
     [Google Scholar]
  86. HiguchiS. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: A randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study).J. Clin. Psychiatry201576218118810.4088/JCP.13m0894025742205
     [Google Scholar]
  87. MaiselN.C. BlodgettJ.C. WilbourneP.L. HumphreysK. FinneyJ.W. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?Addiction2013108227529310.1111/j.1360‑0443.2012.04054.x23075288
     [Google Scholar]
  88. SkinnerM.D. LahmekP. PhamH. AubinH.J. Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis.PLoS One201492e8736610.1371/journal.pone.008736624520330
     [Google Scholar]
  89. YoshimuraA. KimuraM. NakayamaH. MatsuiT. OkudairaF. AkazawaS. OhkawaraM. ChoT. KonoY. HashimotoK. KumagaiM. SahashiY. RohS. HiguchiS. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial.Alcohol. Clin. Exp. Res.201438257257810.1111/acer.1227824117666
     [Google Scholar]
  90. LiJ. WangH. LiM. ShenQ. LiX. RongX. PengY. Efficacy of pharmacotherapeutics for patients comorbid with alcohol use disorders and depressive symptoms—A bayesian network meta-analysis.CNS Neurosci. Ther.202026111185119710.1111/cns.1343732686291
     [Google Scholar]
  91. MintzC.M. HartzS.M. FisherS.L. RamseyA.T. GengE.H. GruczaR.A. BierutL.J. A cascade of care for alcohol use disorder: Using 2015–2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care.Alcohol. Clin. Exp. Res.20214561276128610.1111/acer.1460933993541
     [Google Scholar]
  92. FinnS.W. MejldalA. NielsenA.S. Public stigma and treatment preferences for alcohol use disorders.BMC Health Serv. Res.20232317610.1186/s12913‑023‑09037‑y36694198
     [Google Scholar]
  93. JonesK.O. LopesS. ChenL. ZhangL. ZinzowH. JindalM. MclainM. ShiL. Perceptions about mindfulness-based interventions among individuals recovering from opioid and alcohol use disorders: Findings from focus groups.Complement. Ther. Med.20194613113510.1016/j.ctim.2019.07.01331519269
     [Google Scholar]
  94. BurnetteE.M. NietoS.J. GrodinE.N. MeredithL.R. HurleyB. MiottoK. GillisA.J. RayL.A. Novel agents for the pharmacological treatment of alcohol use disorder.Drugs202282325127410.1007/s40265‑021‑01670‑335133639
     [Google Scholar]
  95. YangL.H. WongL.Y. GrivelM.M. HasinD.S. Stigma and substance use disorders.Curr. Opin. Psychiatry201730537838810.1097/YCO.000000000000035128700360
     [Google Scholar]
  96. ParkY.S. ParkS.M. JunJ.Y. KimS.J. Psychiatry in former socialist countries: Implications for north korean psychiatry.Psychiatry Investig.201411436337010.4306/pi.2014.11.4.36325395966
     [Google Scholar]
  97. HammarlundR.A. CrapanzanoK.A. LuceL. MulliganL.A. WardK.M. Review of the effects of self-stigma and perceived social stigma on the treatment-seeking decisions of individuals with drug- and alcohol-use disorders.Subst. Abuse Rehabil.2018911513610.2147/SAR.S18325630538599
     [Google Scholar]
  98. WalkerJ.R. KorteJ.E. McRae-ClarkA.L. HartwellK.J. Adherence across FDA-approved medications for alcohol use disorder in a veterans administration population.J. Stud. Alcohol Drugs201980557257710.15288/jsad.2019.80.57231603760
     [Google Scholar]
  99. HellM.E. NielsenA.S. Does patient involvement in treatment planning improve adherence, enrollment and other treatment outcome in alcohol addiction treatment? A systematic review.Addict. Res. Theory202028653754510.1080/16066359.2020.1723083
     [Google Scholar]
  100. RayL.A. BujarskiS. GrodinE. HartwellE. GreenR. VenegasA. LimA.C. GillisA. MiottoK. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder.Am. J. Drug Alcohol Abuse201945212414010.1080/00952990.2018.152826530373394
     [Google Scholar]
  101. van AmsterdamJ. BlankenP. SpijkermanR. van den BrinkW. HendriksV. The added value of pharmacotherapy to cognitive behavior therapy and vice versa in the treatment of alcohol use disorders: A systematic review.Alcohol Alcohol.2022576agac04310.1093/alcalc/agac04336085572
     [Google Scholar]
  102. SegherK. HuysL. DesmetT. SteenE. ChysS. BuylaertW. De PaepeP. Recognition of a disulfiram ethanol reaction in the emergency department is not always straightforward.PLoS One20201512e024322210.1371/journal.pone.024322233270785
     [Google Scholar]
  103. LiQ. OkadaY. MarczakE. WilsonW.A. LazarusL.H. SwartzwelderH.S. The novel micro-opioid receptor antagonist, [N-allyl-Dmt(1)]endomorphin-2, attenuates the enhancement of GABAergic neurotransmission by ethanol.Alcohol Alcohol.2008441131910.1093/alcalc/agn08518971291
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673248999231013043249
Loading
The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder
Curr. Med. Chem. 31, 6393 (2024); https://doi.org/10.2174/0109298673248999231013043249
/content/journals/cmc/10.2174/0109298673248999231013043249
/content/journals/cmc/10.2174/0109298673248999231013043249
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alcohol; alcohol dependence treatment; alcohol use disorder; D2R dopamine receptors; dopamine receptors; opioid receptors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test